NCI

April 29, 2021

Genetic ancestry and hypertension risk

Racial disparities in hypertension risk are due in part to genetic differences between ancestries, Vanderbilt investigators find in a study of participants in the Million Veteran Program.

By Bill Snyder
April 20, 2021

New therapeutic strategy for leukemia syndrome

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

By Leigh MacMillan
From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

By Leigh MacMillan
Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

By Leigh MacMillan
March 23, 2021

Prostate cancer microenvironment

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

By Leigh MacMillan
March 9, 2021

Markers for breast cancer progression

Vanderbilt researchers clarify how a microRNA associated with triple-negative breast cancer survival inhibits cancer progression, suggesting new treatment strategies.

By Sarah E. Glass